Therapeutic agents that target the TGF‐β pathway, either alone or in combination with other tumour‐promoting pathways such as PD‐L193 and VEGF94 within TME have illustrated encouraging efficacy, albeit most remained at pre‐clinical and phase 1 trial status. The gene discussed is TGFB1; the disease is neoplasm.